Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2013-07-12

FDA Approved: TRI-LUMA — Supplemental Application (Galderma Laboratories, L.P.)

View source ↗

Summary

FDA approved a supplemental application for TRI-LUMA, a combination of fluocinolone acetonide, hydroquinone, and tretinoin, submitted by Galderma Laboratories, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tri-Luma (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%)

Snippet

SUPPL AP for TRI-LUMA (FLUOCINOLONE ACETONIDE, HYDROQUINONE, AND TRETINOIN)